DENMEAD, England – June 28, 2012: Microsulis Medical Ltd will be exploring microwave ablation’s (MWA) therapeutic role at a major surgical conference in Paris next week. The microwave ablation specialist’s Satellite Symposium is part of the industry programme at the 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA), which will be attended by 2,500 clinicians from across the globe.

Microsulis, an IHPBA gold sponsor, specialises in minimally invasive microwave technology for the coagulation, or destruction, of soft tissue. Clinicians have successfully used the company’s Acculis MTA system for interventional therapy and as an aid to resection, coagulating tissue in the liver, lung and kidney.

 

Leading Microsulis Medical’s IHPBA symposium will be some of the international surgical community’s established microwave users:

·         Moderator - Professor John Primrose, University Hospital Southampton, UK

·         Speaker - Dr David Iannitti, Carolinas Medical Center, US

·         Speaker - Associate Professor Eduard Jonas, Karolinska University Hospital, Sweden

·         Speaker - Professor Bernard Nordlinger, Hôpital Ambroise Paré, France.

 

Dr Iannitti will open the presentations by sharing his experience of how to use microwave ablation in surgery. Associate Professor Jonas will follow with a study of the application of microwave to achieve the best outcomes in different procedures. Professor Nordlinger will then investigate ablation’s role in conjunction with surgery and chemotherapy.

The presentations will be followed by a panel discussion to consider what trials are needed to define MWA’s role in the surgical community’s armamentarium.

The symposium ‘Is MWA now an established therapy? Where does it fit and how do we evidence it?’ takes place in Room Maillot, at the Palais des Congrès de Paris, between 12.30pm and 2pm, on Tuesday July 3. Find out more about the symposium and Microsulis Medical’s devices by visiting booth 29 in the exhibition hall. 

Microsulis Medical is a specialist medical device company with market leading solutions in microwave ablation. The company’s products deliver significant technological and clinical advances to physicians and patients in minimally invasive, soft tissue ablation. 

The Acculis MTA system is distributed globally, with the exception of the US, by AngioDynamics: www.AngioDynamics.com.

More information is available at www.microsulis.com.

The FDA has cleared the Acculis MTA system for the coagulation of soft tissue. The Acculis MTA system has not been cleared or approved for any specific treatments or therapies of a specific disease or condition that may be mentioned in this press release.